Northside Capital Management LLC Purchases New Stake in Stryker Corporation $SYK

Northside Capital Management LLC purchased a new stake in Stryker Corporation (NYSE:SYK) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 900 shares of the medical technology company’s stock, valued at approximately $356,000.

A number of other large investors have also added to or reduced their stakes in SYK. Brighton Jones LLC raised its stake in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the period. Ameriflex Group Inc. bought a new position in Stryker during the 4th quarter worth $95,000. Integrated Advisors Network LLC increased its position in Stryker by 5.5% during the 4th quarter. Integrated Advisors Network LLC now owns 3,415 shares of the medical technology company’s stock worth $1,230,000 after buying an additional 178 shares during the period. Capital A Wealth Management LLC bought a new position in Stryker during the 4th quarter worth $26,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Stryker during the 4th quarter worth $154,140,000. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. BTIG Research reiterated a “buy” rating on shares of Stryker in a research report on Monday, July 14th. Truist Financial set a $415.00 price objective on Stryker and gave the stock a “hold” rating in a research report on Monday, August 4th. Rothschild Redb upgraded Stryker to a “hold” rating in a research report on Thursday, September 18th. Evercore ISI increased their price objective on Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Finally, Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Friday, July 18th. Fourteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $430.33.

Stryker Stock Down 1.3%

SYK stock opened at $373.12 on Wednesday. The company has a market cap of $142.65 billion, a PE ratio of 49.42, a price-to-earnings-growth ratio of 2.72 and a beta of 0.93. The business has a 50-day simple moving average of $386.91 and a 200 day simple moving average of $379.01. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s dividend payout ratio (DPR) is 44.50%.

Insider Activity

In related news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.20% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.